In the Phase I CHRYSALIS trial evaluating amivantamab in EGFR exon 20 insertion-mutated NSCLC, there was an incidence of 3.3% for all-grade pneumonitis, with 0.7% of patients experiencing grade 3 or higher events [30,64]. This evidence concerns the gene EGFR and pneumonitis.